The Lucid Study was a prospective, multicentre feasibility trial evaluating the LumenEye® digital rectoscope as a tool for triaging patients with lower gastrointestinal (GI) symptoms in a primary care setting. Conducted across multiple GP practices, the study aimed to assess whether the integration of LumenEye into routine general practice could improve early diagnosis of colorectal conditions, reduce secondary care referrals, and enhance patient satisfaction.
Results from the study showed that LumenEye was both safe and well tolerated by patients. It demonstrated 100% sensitivity for detecting colorectal cancer, and GPs reported increased diagnostic confidence. The device also allowed immediate visualisation of the rectum, supporting quicker decision-making and improved reassurance for patients.
By embedding this technology in the primary care pathway, the Lucid Study highlights a potentially transformative approach to managing lower GI symptoms. The findings support larger-scale trials and suggest LumenEye could significantly reduce pressure on secondary care services.
